Pfizer has secured approval from the US Food and Drug Administration (FDA) for the subcutaneous use of Fragmin (dalteparin sodium) injection for the treatment of potentially life-threatening blood clots in pediatric patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,